ClearOne Stock Exploded 69% in One Day: The Cortigent Brain-Implant Merger Behind CLRO's Wild Friday

ClearOne (CLRO) stock closed up 69.27% at $3.25 on Friday, October 23, 2026 — one of the biggest moves on the Nasdaq that day.

ClearOne stock is blowing up because traders are piling into a tiny-float Nasdaq name days before its planned merger with brain-implant company Cortigent is expected to close. CLRO surged 69.27% to $3.25 on Friday, October 23, 2026, on roughly 36 million shares traded — a staggering churn for a company with only about 2.68 million shares outstanding. With the Cortigent deal's October closing window now open, merger math, momentum and a very tight float did the rest.

What happened on Friday

ClearOne opened at $1.97, ran as high as $4.69 intraday, and closed at $3.25, up $1.33 (+69.27%) from Thursday's $1.92 close. Volume reached about 36 million shares, against a 50-day relative volume reading of 53.1x — meaning the stock traded dozens of times its normal activity. The shares gave back some ground after the bell, slipping about 9% to $2.94 in extended trading, a reminder of how fast micro-cap momentum can reverse. Even after Friday's jump, CLRO sits far below its 52-week high of $16.50, with a market value of only about $8.7 million at the close.

Why it's blowing up: the Cortigent merger

ClearOne is no longer really an audio-conferencing story. The company sold its operating assets and kept its Nasdaq listing — and on July 1, 2026, it signed a definitive merger agreement to acquire Cortigent, Inc., the neurostimulation subsidiary of Vivani Medical (NASDAQ: VANI). Cortigent works on brain-computer interface technology, including the Orion Visual Cortical Prosthesis System, an artificial-vision device, and a program aimed at restoring arm and hand mobility after stroke.

Under the deal, a ClearOne merger subsidiary merges into Cortigent, which survives as a wholly owned ClearOne subsidiary. Vivani receives 12,500,000 ClearOne shares for Cortigent. If the deal closes, the combined company plans to rename itself Cortigent Holdings, Inc. and trade on Nasdaq under the new ticker CRGT.

Key facts

Friday's move: CLRO +69.27% to $3.25; intraday range $1.97–$4.69; volume ~36 million shares (53.1x relative volume).
The merger math: Vivani is expected to own about 59.4%–67.5% of the combined company; existing ClearOne shareholders would hold only about 12.7%–14.4% after the new shares are issued.
The financing: Closing requires a $10 million to $15 million equity financing, structured as 2.5 million to 5.0 million units — each one ClearOne share plus a warrant to buy another share at $10.00 for six months.
Approval already cleared: An information statement showed holders of about 61.3% of ClearOne's voting stock approved the 12.5 million-share issuance the deal needs — a key closing hurdle.
Closing window: ClearOne has said it expects pricing and closing of the Cortigent merger to take place in October 2026 — which is why traders are focused on it right now.

The honest caveat: no single new headline did this

No confirmed new company announcement on Friday itself explains the spike. Reporting and market data attribute the move to merger-closing expectations meeting a tiny float and heavy momentum buying — the same pattern that sent CLRO up about 48% in a single session in July when merger filings first spelled out the share counts, and up another 43% in late September when the shareholder approval cleared. When a stock with under a million shares in the float meets a deadline-driven story, volume can overwhelm supply very quickly — in both directions, as Friday's after-hours dip showed.

The risks are just as real

ClearOne disclosed that it received a Nasdaq delisting determination on October 8, 2026, for failing to satisfy the $2.5 million minimum stockholders' equity rule, and said it planned to appeal through a hearing request, which stays any suspension while the appeal proceeds. The company reported a second-quarter 2026 net loss of $914,000 and held just $75,000 in cash at June 30, and it took a $200,000 loan in mid-October. The merger also still depends on completing the financing and satisfying Nasdaq listing requirements. This is a high-risk, highly dilutive micro-cap situation — the story is the deal closing, not the legacy business.

What's next

Watch for the financing pricing, an effective registration statement, and any closing announcement in the remaining days of October. If the Cortigent merger closes, CLRO becomes Cortigent Holdings (CRGT), a neurotechnology company, and today's ClearOne holders become a small minority of it. If the financing or listing conditions fail, the same thin float that powered Friday's 69% surge can amplify a fall just as fast. This post reports what happened and why markets reacted; it is not financial advice.

Sources

FAQ

Why did ClearOne stock jump 69%?
CLRO closed up 69.27% at $3.25 on October 23, 2026, on about 36 million shares traded, as traders positioned for the expected October closing of its merger with Cortigent, Vivani Medical's neurostimulation subsidiary, in a stock with a very small float.

What is the ClearOne–Cortigent merger?
Under the July 1, 2026 agreement, Cortigent becomes a wholly owned ClearOne subsidiary in exchange for 12.5 million ClearOne shares issued to Vivani, and the combined company plans to rename itself Cortigent Holdings and trade as CRGT.

How much of the combined company will current ClearOne shareholders own?
About 12.7%–14.4%, according to the merger filings, while Vivani is expected to hold roughly 59.4%–67.5% — heavy dilution is built into the deal.

What could still stop the deal?
The merger still needs its $10 million–$15 million financing completed and Nasdaq listing conditions satisfied, and ClearOne is separately appealing an October 8 Nasdaq delisting determination over the $2.5 million minimum equity rule.